It belongs to the GLP-1 receptor agonist class and helps reduce appetite, control cravings, and support long-term weight loss
Here is a summary of the findings, which overall indicate a positive safety profile
3 Previous randomized control trials of semaglutide in diabetic and non-diabetic populations have suggested that non-diabetic patients lose more weight than diabetic patients when prescribed semaglutide, but those studies do not represent real-world data and did not evaluate doses lower than 2.4 mg
Patients treated with semaglutide lost an average weight of 15.3 kg , and their average body mass index (BMI) dropped by 5.54
Benefits You May Notice Appetite control and fewer cravings Support for weight reduction within a structured program Metabolic support alongside lifestyle changes Accountability from a dedicated clinical team For practical tips to pair with treatment, read our latest Blogs
The cost relief visible in Canada and India in 2026 does not directly transfer to US pricing in the short term
